Medtronic Plc (NYSE:MDT) reported third-quarter 2025 sales of $8.29 billion, missing the consensus of $8.32 billion. The ...
Medtronic PLC (MDT) reports robust revenue and EPS growth, driven by innovations in Cardiac Ablation and Leadless Pacing, ...
Medtronic (MDT) stock slips as the company reaffirms full-year outlook after delivering mixed financial for Q3 fiscal 2025.
Q3 2025 Earnings Call Transcript February 18, 2025 Medtronic plc beats earnings expectations. Reported EPS is $1.39, ...
Reports Q3 revenue $8.29B, consensus $8.33B. “We delivered strong earnings this quarter, with significant improvements in both our gross margin ...
Medtronic's Q3 adjusted EPS of $1.39 surpassed forecasts by $0.03. Revenue of $8.29 billion fell short of expectations by $40 million. Premarket trading saw a 4.48% drop in Medtronic's stock price.
Medtronic stock was down stock was down today after its third-quarter revenue slightly missed the Wall Street analyst consensus.
The medical device company posted revenue of $8.29 billion in the period, falling short of Street forecasts. Ten analysts surveyed by Zacks expected $8.33 billion. Medtronic expects full-year earnings ...
Medtronic (NYSE: MDT) recently announced its Q3 fiscal 2025 results (fiscal ends in April), reporting revenue of $8.29 billion, slightly below the $8.33 billion consensus estimate. Adjusted ...
Medtronic (NYSE:MDT) traded lower in the premarket on Tuesday after the MedTech giant, with its Q3 FY25 results, reaffirmed its full-year outlook despite a major opportunity to consolidate its ...
Medtronic Q3 revenue of $8.29 billion missed estimates, but EPS of $1.39 beat the $1.36 consensus. Medtronic reaffirms FY25 organic growth guidance of 4.75%-5%. Get ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results